CRISPR/Cas9 genomic editing technology allows the ablation of the BCR/ABL fusion gene, causing an absence of oncoprotein expression, and blocking its tumorigenic effects in vitro and in the in vivo xenograft model of CML. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.